Study on the efficacy and safety of Lactobacillus and its formulations in reducing the bacterial load of Helicobacter pylori

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063231

Enrollment

Unknown

Registered

2022-09-02

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

A2:Lactobacillus plantarum inm28-LP

A3:Lactobacillus plantarum inm28-LP + Lactobacillus helveticus inm25-LH

A4:Lactobacillus plantarum inm28-LP + Lactobacillus helveticus inm25-LH + Lactobacillus paracasei inm25-Lpc + Lactobacillus rhamnosus inm28-LR

B2:Lactobacillus plantarum inm28-LP + Base yogurt (containing 2 kinds of base fermentation bacteria)

B3:Lactobacillus plantarum inm28-LP + Lactobacillus helveticus inm25-LH + Base yogurt (containing 2 kinds of base fermentation bacteria)

B4:Lactobacillus plantarum inm28-LP + Lactobacillus helveticus inm25-LH + Lactobacillus paracasei inm25-Lpc + Lactobacillus rhamnosus inm28-LR + Base yogurt (containing 2 kinds of base fermentation ba

A1:Placebo (no probiotics added)

B1:Base yogurt (containing 2 kinds of base fermentation bacteria)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years, both sexes; 2. C13-UBT positive, no clinical symptoms, or accompanied by anorexia, acid reflux, heartburn, abdominal pain, abdominal distension, nausea and other gastrointestinal symptoms; 3. No previous anti-HP treatment; No antibiotics or probiotics were used for 4 weeks, and no proton pump inhibitors or H2 receptor antagonists were used for 2 weeks. 4. Understand the study content and be willing to cooperate with treatment and follow-up

Exclusion criteria

Exclusion criteria: 1. History of allergy to probiotics or similar probiotics in this study; 2. Gastroscopy showed hemorrhage, pyloric obstruction, perforation, gastrointestinal tumor and other complications; 3. Previous gastrectomy and colectomy; 4. Serious underlying diseases, such as malignant tumors, end-stage renal disease, liver failure, cardiopulmonary disease and other important organ diseases; 5. Pregnant and lactating women; 6. Failure to cooperate agreement.

Design outcomes

Primary

Measure	Time frame
C13 breath test value;	—

Countries

China

Contacts

Public ContactJie Pan

Wenzhou Central Hospital

783202415@qq.com+86 13706658031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026